Page 288 - Read Online

Page 18 of 18 Zhang et al. Hepatoma Res 2019;5:27 I http://dx.doi.org/10.20517/2394-5079.2019.13

cells. ACS Nano 2014;8:12151-66.
180 Wang Z, Tan J, Mcconville C, Kannappan V, Tawari PE, et al. Poly lactic-co-glycolic acid controlled delivery of disulfiram to target liver
cancer stem-like cells. Nanomedicine 2017;13:641-57.
181 Gao H, Li K, Tu H, Pan X, Jiang H, et al. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.
Clin Cancer Res 2014;20:6418-28.
182 Pan QZ, Pan K, Wang QJ, Weng DS, Zhao JJ, et al. Annexin A3 as a potential target for immunotherapy of liver cancer stem-like cells.
Stem Cells 2015;33:354-66.
183 Xu X, Xing B, Hu M, Xu Z, Xie Y, et al. Recurrent hepatocellular carcinoma cells with stem cell-like properties: possible targets for
immunotherapy. Cytotherapy 2010;12:190-200.
184 Jung JW, Yoon SM, Kim S, Jeon YH, Yoon BH, et al. Bone morphogenetic protein-9 is a potent growth inhibitor of hepatocellular
carcinoma and reduces the liver cancer stem cells population. Oncotarget 2016;7:73754-68.
185 Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-
90.
186 Kudo M, Finn RS, Qin S, Han KH, Ikeda K, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable
hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163-73.
187 Bruix J, Qin S, Merle P, Granito A, Huang YH, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on
sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2016;389:56-66.
188 Sprinzl MF, Galle PR. Current progress in immunotherapy of hepatocellular carcinoma. J Hepatol 2017;66:482-4.
189 El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, et al. Nivolumab in patients with advanced hepatocellular carcinoma
(CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-502.
190 Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma
previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018;19:940-52.
191 Rycaj K, Tang DG. Cancer stem cells and radioresistance. Int J Radiat Biol 2014;90:615-21.
192 Morrison R, Schleicher SM, Sun Y, Niermann KJ, Kim S, et al. Targeting the mechanisms of resistance to chemotherapy and radiotherapy
with the cancer stem cell hypothesis. J Oncol 2011;2011:941876.
193 Sun R, Liu Y, Li SY, Shen S, Du XJ, et al. Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic
inhibition of cancer stem cells. Biomaterials 2015;37:405-14.
194 Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010;29:4741-
51.
195 Liu C, Liu L, Shan J, Shen J, Xu Y, et al. Histone deacetylase 3 participates in self-renewal of liver cancer stem cells through histone
modification. Cancer Lett 2013;339:60-9.
196 Fang L, Zhang HB, Li H, Fu Y, Yang GS. miR-548c-5p inhibits proliferation and migration and promotes apoptosis in CD90(+) HepG2
cells. Radiol Oncol 2012;46:233-41.